

Allium Healthcare partners with Neurowyxr to leverage digital neuroscience solutions

12 October 2022 | News

Active Agers in Singapore will have access to innovative and cost-effective brain health assessments, diagnosis, and digital therapy



Allium Healthcare has partnered with Singapore's neuroscience-tech company Neurowyxr, to jointly develop brain health programmes in helping Active Agers screen, monitor, prevent and improve brain health.

Allium will be the first Intermediate and Long-Term care (ILTC) provider in Asia-Pacific to provide Active Ageing programs focused on the brain, using Neurowyxr's Digital Brain Function Screen and future brain health solutions.

World Health Organisation and leading clinical neuroscientists have recommended brain cognitive screening for all adults as part of routine healthcare screening. Early recognition can prevent and reduce the disability of brain health problems that are associated with cognitive decline, stroke, Long Covid brain damage, Parkinson's disease and dementia. This has the potential to enable prevention, early recognition and treatment of brain health problems that affect millions of people in the Asia Pacific.

Allium will provide Neurowyxr's Digital Brain Function Screen that enables early detection of cognitive decline to patients and to design therapies. A digital and gamified solution can be completed on a phone or browser in 14-16 minutes.

Neurowyxr specialises in neuroscience-based digital solutions and will work with Allium to roll out future digital neuroscience solutions such as Digital Brain Health Diagnostics and Digital Therapy.